Getting Ahead Of IgAN: A New Treatment Paradigm For Disease Control Ft. Dr. Brad Rovin : 1 Rare Kidney Disease Show podcast

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

1:03:38

Too many entrepreneurs get stuck on the business treadmill, hustling nonstop, unable to scale, and unknowingly stalling their growth. That’s where Dave Ramsey began. After crashing into $3 million in debt, he rebuilt from scratch, turning a small radio program into a national show with millions of listeners. With over three decades of experience in entrepreneurship, business growth, and content creation, he knows what it takes to build a lasting business. In this episode, Dave reveals the six drivers of long-term success, the five key stages of startup growth, and how he balances life as an entrepreneur and a content creator. In this episode, Hala and Dave will discuss: (00:00) Introduction (00:23) The Core Principles of Financial Freedom (05:42) Adapting to Change as a Content Creator (09:22) Balancing Content Creation and Entrepreneurship (12:34) How to Create a Clear Path in Business (15:19) The Truth About Starting a Business Today (18:22) The Six Drivers of Business Success (26:20) Shifting From Tactical to Strategic Thinking (29:44) The Five Stages of Business Growth (41:10) Leading with Care, Clarity, and Accountability (47:10) Identifying the Right Leadership Skills (48:35) Starting a Media Business as an Entrepreneur Dave Ramsey is a personal finance expert, radio personality, bestselling author, and the founder and CEO of Ramsey Solutions. Over the past three decades, he has built a legacy of helping millions achieve financial freedom. As the host of The Ramsey Show , Dave reaches more than 18 million listeners each week. He is the author of eight national bestselling books. His latest, Build a Business You Love , helps entrepreneurs navigate growth and overcome challenges at every stage. Sponsored By: Shopify - Sign up for a one-dollar-per-month trial period at youngandprofiting.co/shopify OpenPhone: Streamline and scale your customer communications with OpenPhone. Get 20% off your first 6 months at openphone.com/profiting Airbnb - Find yourself a co-host at airbnb.com/host Indeed - Get a $75 sponsored job credit at indeed.com/profiting RobinHood - Receive your 3% boost on annual IRA contributions, sign up at robinhood.com/gold Factor - Get 50% off your first box plus free shipping at factormeals.com/factorpodcast Rakuten - Save while shopping at rakuten.com Microsoft Teams - Stop paying for tools. Get everything you need, for free at aka.ms/profiting LinkedIn Marketing Solutions - Get a $100 credit on your next campaign at linkedin.com/profiting Resources Mentioned: Dave’s Book, Build a Business You Love: bit.ly/BuildaBusinessYouLove Dave’s Website: ramseysolutions.com Active Deals - youngandprofiting.com/deals Key YAP Links Reviews - ratethispodcast.com/yap Youtube - youtube.com/c/YoungandProfiting LinkedIn - linkedin.com/in/htaha/ Instagram - instagram.com/yapwithhala/ Social + Podcast Services: yapmedia.com Transcripts - youngandprofiting.com/episodes-new Entrepreneurship, Entrepreneurship Podcast, Business, Business Podcast, Self Improvement, Self-Improvement, Personal Development, Starting a Business, Strategy, Investing, Sales, Selling, Psychology, Productivity, Entrepreneurs, AI, Artificial Intelligence, Technology, Marketing, Negotiation, Money, Finance, Side Hustle, Mental Health, Career, Leadership, Mindset, Health, Growth Mindset, Side Hustle, Passive Income, Online Business, Solopreneur, Networking.…

Rare Kidney Disease Show «
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1

год назад 16:15

MP3•Главная эпизода

Overview:

In this episode of the Rare Kidney Disease Show, Dr. Rovin, Professor of Internal Medicine and Pathology at Ohio State University and chair of the RKD Scientific Network and Podcast, discusses advances in the management of IgAN through a patient case study.

“IgAN progresses more often than we thought and progresses even in patients with low levels of proteinuria.”
“We continue to strive for greater improvements.”
“Approaching IgAN with targeted therapies can affect different aspects of IgAN pathogenesis.”

Key Takeaways:

Understanding the Underlying IgAN pathophysiology: Highlight the 4-Hit Hypothesis and the intricate disease mechanism (4:27)
IgAN Case Study Introduction (6:57)
Treatment Initiation (8:26)
Management of Progression: Question the outcomes of initial intervention for this patient (9:50)
Foundational Therapy: Optimization for improved outcomes (10:24)
Maintenance Options: Explore available therapies to sustain treatment effectiveness (11:05)
Postulated Algorithm: Discover an algorithm for inflammation management and proteinuria reduction (11:49)
Closing Remarks: Gain insight into future episodes (14:10)

6 эпизодов

Rare Kidney Disease Show

Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1

Rare Kidney Disease Show

published год назад

MP3•Главная эпизода

“IgAN progresses more often than we thought and progresses even in patients with low levels of proteinuria.”
“We continue to strive for greater improvements.”
“Approaching IgAN with targeted therapies can affect different aspects of IgAN pathogenesis.”

Key Takeaways:

Understanding the Underlying IgAN pathophysiology: Highlight the 4-Hit Hypothesis and the intricate disease mechanism (4:27)
IgAN Case Study Introduction (6:57)
Treatment Initiation (8:26)
Management of Progression: Question the outcomes of initial intervention for this patient (9:50)
Foundational Therapy: Optimization for improved outcomes (10:24)
Maintenance Options: Explore available therapies to sustain treatment effectiveness (11:05)
Postulated Algorithm: Discover an algorithm for inflammation management and proteinuria reduction (11:49)
Closing Remarks: Gain insight into future episodes (14:10)

6 эпизодов

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

Все серии

Rare Kidney Disease Show

1
Intro to FSGS - Dr. Howard Trachtman 34:19

3 дня назад34:19

34:19

Title: Intro to FSGS Episode Description: In this episode of the Rare Kidney Disease Show, Howard Trachtman, Adjunct Professor of Pediatrics at the University of Michigan, and Chris Gisler, medical director at Travere Therapeutics, explore the complexities of FSGS, covering its pathophysiology, classifications, and clinical presentation. They discuss key drivers of kidney failure, challenges in diagnosis and management, and the unmet need for safe and effective treatments. Listeners will gain insights into the patient journey, role of precision medicine, disease heterogeneity, and the future of clinical trial design. The episode concludes with how PARASOL is shaping advancements in FSGS research and clinical trials. Key Takeaways: Evolving Classification of FSGS – Once defined primarily by histopathology, FSGS is now recognized as a heterogeneous disorder with distinct genetic, immune, and metabolic etiologies. This shift has critical implications for diagnosis and treatment. FSGS and the Role of Podocyte Injury – Podocyte loss is a key driver of FSGS progression, with genetic, immune, and metabolic insults leading to irreversible damage. Understanding this mechanism is crucial for developing targeted therapies. Challenges in Treatment and Therapeutic Gaps – Current treatment strategies rely on empiric use of steroids and calcineurin inhibitors, with variable efficacy and significant side effects. A more targeted approach is needed to improve patient outcomes. Speakers: Howard Trachtman is the Adjunct Professor of Pediatrics at the University of Michigan. Chris Gisler is a medical director at Travere Therapeutics and a former community nephrologist practicing in Pittsburgh.…

Rare Kidney Disease Show

1
ASN Update - Sparsentan Redefining IgAN Treatment 19:07

11 weeks назад19:07

19:07

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024. Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission. Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy. Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study. These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.…

Rare Kidney Disease Show

1
Rethinking IgAN: A Different Perspective from Community Nephrologists : 4 15:58

33 weeks назад15:58

15:58

Luis Velez, MD is a board-certified community nephrologist in San Antonio, TX with expertise in hypertension and glomerular disorders. Jessica Coleman, MD is a board-certified community nephrologist practicing between Savanah, GA and Charleston, SC with expertise in hypertension and glomerular disorders. In this episode, Drs Velez and Coleman discuss management of IgAN patients from the viewpoint of community nephrologists. They discuss the evolution in their management of IgAN, highlighting the availability of new data such as RaDaR as a key driver of change. With greater awareness of the role of proteinuria, they advocate for early and aggressive treatment to avoid long term complications of IgAN. Key Quotes: “RaDaR taught me that the traditional way of looking at IgA nephropathy is wrong. We realized this is a disease state that absolutely can progress and can progress more rapidly than what we initially appreciated and certainly at a younger age in these patients . (02:25) “When we look at patients with proteinuria, even just 0.5 g/d, a third of patients under 40 are going to progress to end stage kidney disease in ten years [RaDaR].” (04:30) “With the RaDaR data, we see levels of proteinuria 0.5 -0.8 g/d still being significant markers for disease progression.” (08:56) Key Takeaways: IgAN is not a benign disease Proteinuria is the most important prognostic indicator of disease progression in IgA Nephropathy HCPs should be targeting lower proteinuria goals to achieve complete remission <0.3 g/d The updated KDIGO Guidelines should support clinicians’ decisions to target complete remission…

Rare Kidney Disease Show

1
The Role of Endothelin in IgAN, ft. Dr. Donald Kohan : 3 17:25

40 weeks назад17:25

17:25

Episode Overview: Donald Kohan, PhD is an Emeritus Professor at the University of Utah Health with expertise in endothelin receptors, sodium transporters, and the renin-angiotensin-aldosterone system in chronic kidney disease. In this episode, Professor Kohan provides an overview of the endothelin system and how it relates to the pathophysiology of chronic kidney disease and IgA nephropathy specifically. Key Quotes: “Endothelin 1 is a really unusual molecule. It's highly stable because it has 2 interchain disulfide bonds that resist degradation. It's extremely potent having about 10 fold higher potency than any other known vasoactive factor.” “Angiotensin and ET-1 cause their effects through different pathways.” “Angiotensin stimulates transient calcium release, which causes more short-term contraction and other effects. While endothelin 1 stimulates more sustained calcium release, which then elicits longer lasting pathophysiologic effects.” Key Takeaways: (04:41) Endothelin-1 acts via ETA receptors to cause vasoconstriction, fibrosis, cell proliferation and other effects that promote chronic kidney disease (06:15) The endothelin and renin-angiotensin systems interact, forming a vicious cycle that worsens kidney injury (12:19) In IgA nephropathy models, combined ETA + angiotensin receptor blockade with sparsentan reduced proteinuria and kidney injury more than angiotensin blockade alone…

Rare Kidney Disease Show

1
Unmet Needs in IgAN: Burden of Disease & Long-Term Impact on Patients ft. Dr. Jonathan Barratt : 2 15:44

49 weeks назад15:44

15:44

Overview: In this episode of the Rare Kidney Disease Show, Professor Jonathan Barratt discusses the need to take a long-term approach when managing IgA nephropathy patients. He presents data from the UK National Registry of Rare Kidney Diseases (RaDaR). During this recording you will hear Professor Barratt discussing the continued risk of progression to end stage renal disease even in patients with proteinuria of less than 1g/day, the current threshold of high risk as per KDIGO guidelines. The data from the UK has been reinforced by recent database studies and these will also be discussed by Professor Barratt. Key Quotes: "If you have IgA Nephropathy and you're diagnosed as a child, half of those children have developed kidney failure at 20 years." "We need to be thinking, what is it like for that patient in front of us being 50 or 60, not necessarily what's going to happen in the next five or ten years." "If we don't think the longer term, we're going to under-treat and not serve our patients well." Key Takeaways: IgA nephropathy patients often have decades of life ahead of them, so physicians should focus on minimizing lifetime risk of kidney failure rather than short-term outcomes (00:02:11) RaDaR data shows high rates of kidney failure among IgA nephropathy patients in the UK, even those diagnosed and treated as children (00:04:05) Per the RaDaR publication, an eGFR decline of <1 ml/min per 1.73 m2 per year must be the target if patients are to avoid kidney failure (00:06:48) In the UK, 1 in 4 IgA nephropathy patients with 0.5-1 g/day proteinuria reach ESRD within 10 years (00:08:23) Recent US database searches confirm high rates of CKD progression and kidney failure in IgA nephropathy patients, even those with lower proteinuria levels (00:13:20)…

Rare Kidney Disease Show

1
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1 16:15

1 year назад16:15